Stimulation of glycogenolysis by adenine nucleotides in the perfused rat liver.

Infusion of adenine nucleotides and adenosine into perfused rat livers resulted in stimulation of hepatic glycogenolysis, transient increases in the effluent perfusate [3-hydroxybutyrate]/[acetoacetate] ratio, and increased portal vein pressure. In livers perfused with buffer containing 50 microM-Ca2+, transient efflux of Ca2+ was seen on stimulation of the liver with adenine nucleotides or adenosine. ADP was the most potent of the nucleotides, stimulating glucose output at concentrations as low as 0.15 microM, with half-maximal stimulation at approx. 1 microM, and ATP was slightly less potent, half-maximal stimulation requiring 4 microM-ATP. AMP and adenosine were much less effective, doses giving half-maximal stimulation being 40 and 20 microM respectively. Non-hydrolysed ATP analogues were much less effective than ATP in promoting changes in hepatic metabolism. ITP, GTP and GDP caused similar changes in hepatic metabolism to ATP, but were 10-20 times less potent than ATP. In livers perfused at low (7 microM) Ca2+, infusion of phenylephrine before ATP desensitized hepatic responses to ATP. Repeated infusions of ATP in such low-Ca2+-perfused livers caused homologous desensitization of ATP responses, and also desensitized subsequent Ca2+-dependent responses to phenylephrine. A short infusion of Ca2+ (1.25 mM) after phenylephrine infusion restored subsequent responses to ATP, indicating that, during perfusion with buffer containing 7 microM-Ca2+, ATP and phenylephrine deplete the same pool of intracellular Ca2+, which can be rapidly replenished in the presence of extracellular Ca2+. Measurement of cyclic AMP in freeze-clamped liver tissue demonstrated that adenosine (150 microM) significantly increased hepatic cyclic AMP, whereas ATP (15 microM) was without effect. It is concluded that ATP and ADP stimulate hepatic glycogenolysis via P2-purinergic receptors, through a Ca2+-dependent mechanism similar to that in alpha-adrenergic stimulation of hepatic tissue. However, adenosine stimulates glycogenolysis via P1-purinoreceptors and/or uptake into the cell, at least partially through a mechanism involving increase in cyclic AMP. Further, the hepatic response to adenine nucleotides may be significant in regulating hepatic glucose output in physiological and pathophysiological states.     

Dimethylnitramine metabolism in vitro by NZR rat liver slices

The net metabolism of dimethylnitramine (DMNO) was studied in NZR rat liver slices in tissue culture medium (Dulbecco's MEM). In rats, mice and fish, liver is the principal target organ for DMNO carcinogenesis. Destruction of DMNO in vitro with oxygenated medium was linear with amount of tissue (0.3-3.0 g liver), and with substrate concentration (0.14-4.44 mM). Substrate destruction (initially 0.2 mM DMNO) was linear for 60 min (average rate 0.9 +/- 0.1 microgram DMNO/g liver/min) and then slowed to become linear again at about half the initial rate from 90 min to longer than 5 h. In anoxic (N2) conditions DMNO metabolism slowed or stopped completely after 70 min. Metabolism of dimethylnitrosamine (DMN) was studied in the same preparation. DMN destruction rates were initially about 50% higher than DMNO, but were equal at longer incubation times. Simultaneous metabolism of DMNO and DMN by the same tissue slices showed DMNO rates unaltered in the presence of equimolar DMN (0.24 mM), but DMN rates were 20-40% depressed. No evidence was found for the oxidation of DMN to form DMNO, or for reduction of DMNO to DMN.     

Stimulation of glycogenolysis by epinephrine and glucagon and its inhibition by insulin in isolated rat liver hepatocytes

Rat liver hepatocytes were isolated by collagenase $\text{in vitro}$ perfusion technique and the effect of epinephrine, glucagon and insulin on glycogenolysis was studied. Both glucagon and epinephrine at the concentration of 10^?6M, stimulated gluconeogenesis by 80–100%. Addition of insulin (33 μUnits/ml) completely abolished the epinephrine-stimulated glycogenolysis whereas only 50% inhibition was observed with insulin in glucagon stimulated glycogenolysis. This stimulation was observed within 2–5 min after the addition of the hormones. These results suggest that hepatocytes isolated with low concentrations of collagenase retain glucagon, epinephrine and insulin receptor sites.     

Stimulation of glycogenolysis and vasoconstriction by adenosine and adenosine analogues in the perfused rat liver.

Infusion of adenosine into perfused rat livers resulted in transient increases in glucose output, portal-vein pressure, the effluent perfusate [lactate]/[pyruvate] ratio, and O2 consumption. 8-Phenyltheophylline (10 microM) inhibited adenosine responses, whereas dipyridamole (50 microM) potentiated the vasoconstrictive effect of adenosine. The order of potency for adenosine analogues was: 5'-N-ethylcarboxamidoadenosine (NECA) greater than L-phenylisopropyladenosine greater than cyclohexyladenosine greater than D-phenylisopropyladenosine greater than 2-chloroadenosine greater than adenosine, consistent with adenosine actions modulated through P1-purine receptors of the A2-subtype. Hepatic responses exhibited homologous desensitization in response to repeated infusion of adenosine. Adenosine effects on the liver were attenuated at lower perfusate Ca2+ concentrations. Indomethacin decreased hepatic responses to both adenosine and NECA. Whereas adenosine stimulated glycogen phosphorylase activity in isolated hepatocytes, NECA caused no effect in hepatocytes. The response to adenosine in hepatocytes was inhibited by dipyridamole (50 microM), but not 8-phenyltheophylline (10 microM). The present study indicates that, although adenosine has direct effects on parenchymal cells, indirect effects of adenosine, mediated through the A2-purinergic receptors on another hepatic cell type, appear to play a role in the perfused liver.     

Stimulation of glycogenolysis and vasoconstriction in the perfused rat liver by the thromboxane A2 analogue U-46619

Infusion of the thromboxane A2 analogue U-46619 into isolated perfused rat livers resulted in dose-dependent increases in glucose output and portal vein pressure, indicative of constriction of the hepatic vasculature. At low concentrations, e.g. less than or equal to 42 ng/ml, glucose output occurred only during agonist infusion; whereas at concentrations greater than or equal to 63 ng/ml, a peak of glucose output also was observed upon termination of agonist infusion coincident with relief of hepatic vasoconstriction. Effluent perfusate lactate/pyruvate and beta-hydroxybutyrate/acetoacetate ratios increased significantly in response to U-46619 infusion. Hepatic oxygen consumption increased at low U-46619 concentrations (less than or equal to 20 ng/ml) and became biphasic with a transient spike of increased consumption followed by a prolonged decrease in consumption at higher concentrations. Increased glucose output in response to 42 ng/ml U-46619 was associated with a rapid activation of glycogen phosphorylase, slight increases in tissue ADP levels, and no increase in cAMP. At 1000 ng/ml, U-46619 activation of glycogen phosphorylase was accompanied by significant increases in tissue levels of AMP and ADP, decreases in ATP, and slight increases in cAMP. In isolated hepatocytes, U-46619 did not stimulate glucose output or activate glycogen phosphorylase. Reducing the perfusate calcium concentration from 1.25 to 0.05 mM resulted in a marked reduction of the glycogenolytic response to U-46619 (42 ng/ml) with no efflux of calcium from the liver. U-46619-induced glucose output and vasoconstriction displayed a similar dose dependence upon the perfusate calcium concentration. Thus, U-46619 exerts a potent agonist effect on glycogenolysis and vasoconstriction in the perfused rat liver. The present findings support the concept that U-46619 stimulates hepatic glycogenolysis indirectly via vasoconstriction-induced hypoxia within the liver.     

Stimulation of gluconeogenesis by somatostatin in rat kidney cortex slices.

The effect of somatostatin on gluconeogenesis was studied in kidney cortex slices. Addition of somatostatin (2 μg) stimulated gluconeogenesis from lactate, pyruvate and glutamine by 42%, 50% and 68% respectively. Stimulation of glucose synthesis from lactate by somatostatin was found to be linear with time and dose dependent between 0.1 and 20 μg. Somatostatin-stimulated gluconeogenesis was inhibited by phentolamine (10 μM) but not by propranolol (10 μM) suggesting that somatostatin action is mediated by α-adrenergic stimuli.     

Effect of adrenaline, hydrocortisone, insulin and dibutyryl-cAMP on glycolysis and glycogenolysis in white rat liver slices]

Epinephrine, hydrocortisone, and dibutyril cAMP inhibited glycolysis and glucogenolysis. The inhibitory effect was also found when glucose-6-phosphate (G-6-P) was used as a glycolysis substrate, but not for fructose-1,6-diphosphate. This is the evidence of hexokinase activity inhibition by hormones and dibutyril cAMP, and presumably of phospholylase and phosphofructokinase as well. In the simulated cell-free system the hormones produced no effect, dibutyril cAMP inhibiting hexokinase alone. For the realization of hormones effect their interaction with the cell membrane is required. Inhibition of glycogen and G-6-P decomposition to lactic acid in the rat liver slices was not associated with the hormone action on phosphorylase and phosphofructokinase through cAMP and proteinkinase directly. The results obtained indicated the existence of a supplementary mechanism that modified cAMP effect on the activity of the said enzymes. Insulin was effective in any of the cases.     

Stimulation of hepatic glycogenolysis by acetylglyceryl ether phosphorylcholine

1-O-Alkyl-2-acetyl-sn-glyceryl 3-phosphorylcholine or acetylglyceryl ether phosphorylcholine (AGEPC) stimulated glycogenolysis in perfused livers from fed rats at concentrations as low as 10(-11) M. At the lower AGEPC concentrations, e.g. 2 X 10(-10) M, a single transient phase of enhanced hepatic glucose output was elicited upon infusion of this agonist. At higher concentrations, e.g. 2 X 10(-8) M, a sharp transient spike of glucose output was observed, followed by a stable elevated steady state rate of glucose output until the AGEPC infusion was terminated. Increased rates of lactate and acetoacetate output and a diminished hepatic oxygen consumption were characteristic of the response of the livers to AGEPC at 2 X 10(-10) M. Neither alpha- nor beta-adrenergic antagonists blocked the glycogenolytic response of AGEPC. Repeated infusion of AGEPC led to homologous desensitization of the response, but the response of the liver to the alpha-adrenergic agonist, phenylephrine, or to glucagon, subsequent to AGEPC stimulation, was unaffected. Increasing the period of perfusion between successive additions of AGEPC, from 7 to 30 min, resulted in an increased glycogenolytic response to this agonist. When the perfusate calcium concentration was reduced from 1.25 to 0.05 mM, the glycogenolytic response to AGEPC was markedly diminished; calcium efflux from the liver following stimulation with AGEPC was not observed. The data presented in this study illustrate a potent agonist effect of AGEPC on the glycogenolytic system in the rat liver.